206 related articles for article (PubMed ID: 28575321)
1. The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study.
Østergaard SD; Foldager L; Mors O; Bech P; Correll CU
Schizophr Bull; 2018 Feb; 44(2):453-462. PubMed ID: 28575321
[TBL] [Abstract][Full Text] [Related]
2. PANSS-6: a brief rating scale for the measurement of severity in schizophrenia.
Østergaard SD; Lemming OM; Mors O; Correll CU; Bech P
Acta Psychiatr Scand; 2016 Jun; 133(6):436-44. PubMed ID: 26558537
[TBL] [Abstract][Full Text] [Related]
3. The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia.
Østergaard SD; Foldager L; Mors O; Bech P; Correll CU
Acta Psychiatr Scand; 2018 Nov; 138(5):420-431. PubMed ID: 30168131
[TBL] [Abstract][Full Text] [Related]
4. Early improvement in PANSS-30, PANSS-8, and PANSS-6 scores predicts ultimate response and remission during acute treatment of schizophrenia.
Lin CH; Lin HS; Lin SC; Kuo CC; Wang FC; Huang YH
Acta Psychiatr Scand; 2018 Feb; 137(2):98-108. PubMed ID: 29280500
[TBL] [Abstract][Full Text] [Related]
5. [Symptomatic remission and its relationship to social functioning in Tunisian out-patients with schizophrenia].
El Gharbi I; Chhoumi M; Mechri A
Encephale; 2019 Feb; 45(1):15-21. PubMed ID: 29195805
[TBL] [Abstract][Full Text] [Related]
6. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
8. Inter-rater reliability of ratings on the six-item Positive and Negative Syndrome Scale (PANSS-6) obtained using the Simplified Negative and Positive Symptoms Interview (SNAPSI).
Kølbæk P; Blicher AB; Buus CW; Feller SG; Holm T; Dines D; O'Leary KM; Sørensen RS; Opler M; Correll CU; Mors O; Bech P; Østergaard SD
Nord J Psychiatry; 2018 Aug; 72(6):431-436. PubMed ID: 30037286
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data.
Earley W; Guo H; Daniel D; Nasrallah H; Durgam S; Zhong Y; Patel M; Barabássy Á; Szatmári B; Németh G
Schizophr Res; 2019 Feb; 204():282-288. PubMed ID: 30172595
[TBL] [Abstract][Full Text] [Related]
10. Item response analysis of the Positive and Negative Syndrome Scale.
Santor DA; Ascher-Svanum H; Lindenmayer JP; Obenchain RL
BMC Psychiatry; 2007 Nov; 7():66. PubMed ID: 18005449
[TBL] [Abstract][Full Text] [Related]
11. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia.
Harvey RC; James AC; Shields GE
CNS Drugs; 2016 Jan; 30(1):27-39. PubMed ID: 26801655
[TBL] [Abstract][Full Text] [Related]
12. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study.
Levine SZ; Rabinowitz J; Ascher-Svanum H; Faries DE; Lawson AH
Schizophr Res; 2011 Dec; 133(1-3):42-6. PubMed ID: 22000938
[TBL] [Abstract][Full Text] [Related]
13. [A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS].
Loas G; Noisette C; Legrand A; Delahousse J
Encephale; 1997; 23(1):10-8. PubMed ID: 9172962
[TBL] [Abstract][Full Text] [Related]
14. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
[TBL] [Abstract][Full Text] [Related]
15. Clinical validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview.
Kølbæk P; Dines D; Holm T; Blicher AB; Sørensen RD; O'Leary KM; Feller SG; Buus CW; Nielsen CM; Opler M; Mors O; Correll CU; Østergaard SD
J Psychopharmacol; 2021 Sep; 35(9):1081-1090. PubMed ID: 33779360
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors.
Fleischhacker W; Galderisi S; Laszlovszky I; Szatmári B; Barabássy Á; Acsai K; Szalai E; Harsányi J; Earley W; Patel M; Németh G
Eur Psychiatry; 2019 May; 58():1-9. PubMed ID: 30738380
[TBL] [Abstract][Full Text] [Related]
17. Disparity between General Symptom Relief and Remission Criteria in the Positive and Negative Syndrome Scale (PANSS): A Post-treatment Bifactor Item Response Theory Model.
Anderson AE; Reise SP; Marder SR; Mansolf M; Han C; Bilder RM
Innov Clin Neurosci; 2017 Dec; 14(11-12):41-53. PubMed ID: 29410936
[No Abstract] [Full Text] [Related]
18. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis.
Citrome L; Meng X; Hochfeld M
Schizophr Res; 2011 Sep; 131(1-3):75-81. PubMed ID: 21700430
[TBL] [Abstract][Full Text] [Related]
19. Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data.
Moriguchi S; Bies RR; Remington G; Suzuki T; Mamo DC; Watanabe K; Mimura M; Pollock BG; Uchida H
J Clin Psychopharmacol; 2013 Oct; 33(5):682-5. PubMed ID: 23899638
[TBL] [Abstract][Full Text] [Related]
20. Symptom structure and severity: a comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia.
Stefanovics EA; Krystal JH; Rosenheck RA
Compr Psychiatry; 2014 May; 55(4):887-95. PubMed ID: 24602497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
